Nuvalent, Inc.
NUVL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NUVL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company developing selective kinase inhibitors for cancer, with lead candidates zidesamtinib and neladalkib in Phase 2/3 trials and a cash runway into 2029.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$9.79B
Cash Runway
40.2 moLead Asset
Neladalkib (Phase 1/Phase 2)Next Catalyst
Phase3_Topline · Dec 1, 2029Financial data as of Mar 31, 2026.
Tracking 3 pipeline candidates · 6 clinical trials · 1 catalyst · 1 FDA decision for Nuvalent, Inc..
Nuvalent, Inc. is a clinical-stage biopharmaceutical company developing selective kinase inhibitors for cancer, with lead candidates zidesamtinib and neladalkib in Phase 2/3 trials and a cash runway into 2029.
- Lead product candidates include zidesamtinib (ROS1 inhibitor) and neladalkib (ALK inhibitor), both in Phase 2/3 clinical trials [sec_mda · as of 2026-05-07].
- As of March 31, 2026, the company reported cash & equivalents of $159.7M and total cash, cash equivalents and marketable securities of $1.3 billion, expected to fund operations into 2029 [sec_mda · as of 2026-05-07].
- Net loss for the three months ended March 31, 2026 was $109.3 million; accumulated deficit was $853.7 million as of September 30, 2025 [sec_mda · as of 2026-05-07][sec_mda · as of 2025-10-30].
- The company has no approved products and has not generated any product revenue [sec_mda · as of 2026-05-07].
- Corporate goals for 2025 included advancing zidesamtinib toward NDA submission, transitioning neladalkib into Phase 2, and initiating a Phase 1 trial for NVL-330 [sec · filed 2025-04-28].
What works
- Strong cash position of $1.3 billion in cash, cash equivalents and marketable securities as of May 7, 2026, providing runway into 2029 [sec_mda · as of 2026-05-07].
- Lead candidate zidesamtinib showed 11.1+ months with no CNS progression among responders in the TKI-naïve cohort of the ARROS-1 trial as of June 2025 [sec · filed 2025-06-24].
- Multiple pipeline programs in clinical development (zidesamtinib, neladalkib, NVL-330) targeting validated kinase targets [sec_mda · as of 2026-05-07].
What to weigh
- No approved products and no revenue from product sales; significant net losses since inception [sec_mda · as of 2026-05-07].
- Accumulated deficit of $853.7 million as of September 30, 2025, with net loss of $109.3 million in Q1 2026 alone [sec_mda · as of 2025-10-30][sec_mda · as of 2026-05-07].
- Dependence on successful development, regulatory approval, and commercialization of product candidates to generate revenue [sec_mda · as of 2026-05-07].
- Cash runway may not be sufficient to fund all product candidates through regulatory approval, requiring additional capital [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Cash and marketable securities of $1.3 billion as of May 7, 2026
“we had cash, cash equivalents and marketable securities of $1.3 billion.”
SEC MD&A · May 7, 2026
Net loss of $109.3 million for Q1 2026
“We reported net losses of $109.3 million for the three months ended March 31, 2026”
SEC MD&A · May 7, 2026
Accumulated deficit of $853.7 million as of September 30, 2025
“As of September 30, 2025, we had an accumulated deficit of $853.7 million.”
SEC MD&A · October 30, 2025
No approved products and no product revenue
“We do not have any products approved for sale and have not generated revenue from product sales or any other source.”
SEC MD&A · May 7, 2026
Catalyst timeline
- 2029-12-01 · Phase3_Topline — Phase 3 Topline: A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alec — Topline data from the Phase 3 trial of neladalkib (NVL-655) versus standard of care in ALK-positive non-small cell lung cancer will be a key value inflection point.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Company has no approved products and no product revenue; depends entirely on clinical success [sec_mda · as of 2026-05-07].
- Significant accumulated deficit — Accumulated deficit of $853.7M as of Sep 2025; net loss of $109.3M in Q1 2026 [sec_mda · as of 2025-10-30][sec_mda · as of 2026-05-07].
- Need for additional capital — Cash may not be sufficient to fund all candidates through regulatory approval; may need to raise capital [sec_mda · as of 2026-05-07].
- Clinical and regulatory uncertainty — Success depends on clinical trial outcomes, regulatory approvals, and commercialization [sec_mda · as of 2026-05-07].
What to watch
- Phase 3 topline data for NVL-655 (neladalkib) expected December 1, 2029 [catalyst_timeline].
- Progress of zidesamtinib toward NDA submission and updated data presentations [sec · filed 2025-04-28].
- Initiation and enrollment of Phase 1 trial for NVL-330 [sec · filed 2025-04-28].
- Cash burn rate and any future capital raises as runway extends into 2029 [sec_mda · as of 2026-05-07].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Nuvalent, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nuvalent, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
40.2 months
D/E 0.13 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
1 upcoming, next in ~1189d
0 buys · 66 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
261
Total value held
$7.68B
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 17,248,450 | $1.77B |
| fmr llc | 9,274,959 | $950.2M |
| vanguard capital management llc | 4,856,976 | $497.6M |
| blackrock, inc. | 4,824,785 | $494.3M |
| perceptive advisors llc | 3,161,010 | $323.8M |
| ra capital management, l.p. | 2,534,145 | $259.6M |
| vanguard portfolio management llc | 2,500,907 | $256.2M |
| janus henderson group plc | 2,475,558 | $253.7M |
| wellington management group llp | 2,470,491 | $253.1M |
| state street corp | 2,035,831 | $208.6M |
Showing top 10 of 261 institutional holders of Nuvalent, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 12.2%
- Days to cover
- 7.7
- Shares short
- 4,586,581
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NUVL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nuvalent, Inc.?
Nuvalent, Inc. is a clinical-stage biopharmaceutical company developing selective kinase inhibitors for cancer, with lead candidates zidesamtinib and neladalkib in Phase 2/3 trials and a cash runway into 2029.
What is Nuvalent, Inc.'s lead drug candidate?
Nuvalent, Inc.'s most advanced tracked candidate is Neladalkib (Phase 1/Phase 2) for Locally Advanced Solid Tumor; Non-small Cell Lung Cancer.
What is Nuvalent, Inc.'s next catalyst?
Nuvalent, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alec" — expected December 1, 2029.
Who is the CEO of Nuvalent, Inc.?
Dr. James R. Porter Ph.D. is the chief executive officer of Nuvalent, Inc. (NUVL).
Where is Nuvalent, Inc. headquartered?
Nuvalent, Inc. (NUVL) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.